BrightSpring Health Services(US:BTSG)2026-02-27 14:32Financial Data and Key Metrics Changes - For Q4 2025, total company revenue was $3.6 billion, representing a 29% increase year-over-year [25] - Full year 2025 total revenue reached $12.9 billion, reflecting a 28% growth from 2024 [28] - Adjusted EBITDA for Q4 was $184 million, a 41% increase compared to Q4 2024, while full year adjusted EBITDA was $618 million, up 34% year-over-year [29][11] - The adjusted EBITDA margin for the company was 4.8%, a 20 basis point increase from 2024 [11] Business Line Data and Key Metrics Changes - Pharmacy Solutions segment revenue for Q4 was $3.2 billion, achieving 32% year-over-year growth, while full year revenue was $11.4 billion, up 31% [25][28] - Provider Services segment revenue in Q4 was $394 million, representing a 13% increase year-over-year, with home healthcare revenue growing 19% to $217 million [27][20] - In the Pharmacy Solutions segment, infusion and specialty revenue was $2.6 billion, growing 43% year-over-year, while home and community pharmacy revenue declined 1% to $593 million [26] Market Data and Key Metrics Changes - The average daily census in home healthcare grew 15% to almost 35,000 in Q4, driven by strong quality metrics and strategic acquisitions [21] - Specialty and infusion script growth was 30% year-over-year in Q4, with total pharmacy script volume at 10.8 million [17] Company Strategy and Development Direction - The company plans to divest the community living business to streamline operations and focus on core patient populations [6] - The acquisition of Amedisys and LHC Home Health Assets is expected to enhance the company's home health capabilities, contributing approximately $30 million to adjusted EBITDA in 2026 [13][35] - The company aims to build a unique and scaled home and community healthcare platform, emphasizing quality outcomes and operational best practices [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future of home health and hospice, anticipating a strong growth trajectory over the next 5 to 10 years [50] - The company expects total revenue growth of approximately 14% year-over-year for 2026, with adjusted EBITDA growth of about 25% [13][34] - Management highlighted the importance of executing sales investments and operational efficiencies to drive volume growth and margin expansion [38][39] Other Important Information - The company achieved a leverage ratio of 2.99 times as of December 31, 2025, down from 4.16 times in 2024, indicating improved financial health [32] - The company is initiating a foundation to support community and patient activities, reflecting its commitment to social responsibility [14] Q&A Session Summary Question: Variability in 2026 Outlook - Management noted consistency in Q1 and emphasized the importance of executing strategies to drive volume growth across businesses [37] Question: LDD Introductions and Landscape - Management confirmed expectations for 16-20 new LDD introductions over the next 12-18 months, with a focus on expanding capabilities [40][41] Question: EBITDA and Margins for Segments - Management indicated broad-based margin expansion is expected due to operational efficiencies and favorable product mix [45][46] Question: Home Health Rate Environment - Management expressed optimism about home health rates, projecting a flat baseline with potential for future increases [50] Question: Specialty Drug Launches and Margins - Management highlighted the multifactorial growth in specialty pharmacy, including brand LDDs and generic conversions, which improve margins [55] Question: Amedisys Asset Margins - Management acknowledged the lower margin profile of the Amedisys assets but expressed confidence in improving margins through integration [61][62] Question: Pharmacy Revenue Guidance Components - Management outlined expected revenue headwinds from IRA impacts and generic conversions but anticipated strong growth across pharmacy businesses [70][71] Question: Infusion Business Update - Management reported double-digit growth in the infusion business and plans for significant investments to enhance capabilities [73][75]